Fluorouracil in colorectal cancer a tale of two drugs: Implications for biochemical modulation

被引:284
作者
Sobrero, AF
Aschele, C
Bertino, JR
机构
[1] UNIV FLORENCE, CHAIR MED ONCOL, FLORENCE, ITALY
[2] MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA
关键词
D O I
10.1200/JCO.1997.15.1.368
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine if fluorouracil (FUra) has different mechanisms of action as a function of the dose schedule used, Design: The preclinical and clinical literature relating toxicity and antitumor effects of FUra as a function of its dose schedule, with and without modulating agents, was reviewed, Results: The data support the hypothesis that FUra may be considered to be two different drugs, depending on its dose schedule (bolus v continuous infusion [CI]). Conclusion: These results suggest that additional therapeutic benefit may be obtained from FUra regimens by (1) appropriate schedule-dependent modulation, (2) the sequential or alternating use of cycles of bolus followed by cycles of CI FUra appropriately modulated, or (3) hybrid regimens, ie, those that contain both pulse and CI schedules. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:368 / 381
页数:14
相关论文
共 173 条
[1]  
ABAD A, 1995, CANCER, V75, P1238, DOI 10.1002/1097-0142(19950315)75:6<1238::AID-CNCR2820750605>3.0.CO
[2]  
2-P
[3]  
AHLGREN JD, 1992, GASTROINTESTINAL ONC, P339
[4]  
[Anonymous], P AM SOC CLIN ONCOL
[5]  
ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO
[6]  
2-2
[7]   A PHASE-II STUDY OF WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE FLUOROURACIL WITH LEUCOVORIN IN COLORECTAL-CARCINOMA [J].
ARDALAN, B ;
CHUA, L ;
TIAN, EM ;
REDDY, R ;
SRIDHAR, K ;
BENEDETTO, P ;
RICHMAN, S ;
LEGASPI, A ;
WALDMAN, S ;
MORRELL, L ;
FEUN, L ;
SAVARAJ, N ;
LIVINGSTONE, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :625-630
[8]  
ARDALAN B, 1980, CANCER RES, V40, P1431
[9]   A RANDOMIZED PHASE-I AND PHASE-II STUDY OF SHORT-TERM INFUSION OF HIGH-DOSE FLUOROURACIL WITH OR WITHOUT N-(PHOSPHONACETYL)-L-ASPARTIC ACID IN PATIENTS WITH ADVANCED PANCREATIC AND COLORECTAL CANCERS [J].
ARDALAN, B ;
SINGH, G ;
SILBERMAN, H .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :1053-1058
[10]   CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER [J].
ARMAND, JP ;
DUCREUX, M ;
MAHJOUBI, M ;
ABIGERGES, D ;
BUGAT, R ;
CHABOT, G ;
HERAIT, P ;
DEFORNI, M ;
ROUGIER, P .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (7-8) :1283-1287